Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg

References

• Hart FD, Boardman PL. Indomethacin: a new non-steroid anti-inflammatory agent. BMJ 1963;2:965–70.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006;8:S3.
   PubMed Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447–61.
   PubMed Web of Science ®Google Scholar
• Argoff CE. Recent developments in the treatment of osteoarthritis with NSAIDs. Curr Med Res Opin 2011;27:1315–27.
   PubMed Web of Science ®Google Scholar
• Indomethacin capsules. Published July 2010 Available from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4babe1c2-15f2-40af-b326-b256507a921c. Revised May 2014 Accessed July 28, 2014.
   Google Scholar
• Mattila MA, Ahlstrom-Bengs E, Pekkola P. Intravenous indomethacin or oxycodone in prevention of post-operative pain. BMJ 1983;287:1026.
   PubMed Web of Science ®Google Scholar
• Schumacher HR. Jr. Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis. J Clin Rheumatol 2004;10:S18–25.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Mason L, McQuay HJ, Edwards J. Single dose oral indomethacin for the treatment of acute postoperative pain (Review). Cochrane Database Syst Rev 2010;11:1–15.
   Google Scholar
• Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin 2007;23:1685–91.
   PubMed Web of Science ®Google Scholar
• Velo GP, Milanino R. Nongastrointestinal adverse reactions to NSAID. J Rheumatol Suppl 1990;20:42–5.
   PubMedGoogle Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769–79.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098.
   PubMed Web of Science ®Google Scholar
• Bueno H, Bardaji A, Patrignani P, Martin-Merino E, Garcia-Rodriguez LA. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010;105:1102–6.
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3:395–405.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628–36.
   PubMed Web of Science ®Google Scholar
• Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006;164:881–9.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Public health advisory—FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm. Published April 2005 Accessed July 28, 2014.
   Google Scholar
• Iroko Pharmaceuticals Press Release. Results from a phase 3 study show Iroko’s investigational submicron indomethacin provided effective pain relief at lower doses. Available from https://www.iroko.com/press-releases/results-from-a-phase-3-study-show-irokos-investigational-submicron-indomethacin-provided-effective-pain-relief-at-lower-doses/. Published December 07, 2012 Accessed July 28, 2014.
   Google Scholar
• Tivorbex Full Prescribing Information. Revised February 2014 Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204768s000lbl.pdf. Accessed July 28, 2014.
   Google Scholar
• Manvelian G, Daniels S, Altman R. A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin. Postgrad Med 2012;124:197–205.
   PubMed Web of Science ®Google Scholar
• Manvelian G, Hochberg MC, Daniels SE, Altman RD, Young CL. A phase 2 study of lower-dose, indomethacin submicron particle capsules demonstrates early onset of acute pain relief. Clin J Pain 2014;30:846–51.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Guidance for industry. Immediate release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. Center for Drug Evaluation and Research (CDER). Available from http://www.fda.gov/downloads/Drugs/Guidances/UCM070636.pdf. Published November 1995 Accessed July 28, 2014.
   Google Scholar
• Sirisuth N, Eddington ND. In-vitro-in-vivo correlation definitions and regulatory guidance. Int J Generic Drugs. Available from http://www.iagim.org/pdf/ivivc-01.pdf. Accessed July 28, 2014.
   Google Scholar
• Bankim CN, Sandipan R, Bhaskar M, et al. In vitro–in vivo correlation: application in pharmaceutical development of various dosages forms. J Chem Pharm Res 2011;3:550–64.
   Google Scholar
• Young DB, Devane JG, Butler J. In vitro-in vivo correlations. In: Young DB, Devane JG, Butler J, editors. Advances in experimental medicine and biology. 1st edition. Springer, New York; 1997. p. 423.
   Google Scholar
• Altman R, Daniels S, Young CL. Indomethacin submicron particle capsules provide effective pain relief in patients with acute pain: a phase 3 study. Phys Sportsmed 2013;41:7–15.
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for Good Clinical Practice E6(R1). Available from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Published June 1996 Accessed July 28, 2014.
   Google Scholar
• US Department of Health and Human Services. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. Center for Drug Evaluation and Research (CDER). Available from http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. Published December 2002 Accessed July 28, 2014.
   Google Scholar
• Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. Postgrad Med 2012;124:117–23.
   PubMed Web of Science ®Google Scholar
• Scallion R, Moore KA. Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study. Clin Ther 2009;31:2233–41.
   PubMed Web of Science ®Google Scholar
• Common terminology criteria for adverse events v4.0. Available from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published May 28, 2009 Accessed July 28, 2014.
   Google Scholar
• Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C. Indomethacin serum concentrations in man. Effects of dosage, food, and antacid. Ann Rheum Dis 1976;35:333–8.
   PubMed Web of Science ®Google Scholar
• Wallusch WW, Nowak H, Leopold G, Netter KJ. Comparative bioavailability: influence of various diets on the bioavailability of indomethacin. Int J Clin Pharmacol 1978;16:40–4.
   Google Scholar